Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis
Article in Journal of Gynecologic Oncology (March 2024)
The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.
Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer
Article in Frontiers in Oncology (January 2024)
Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis
Article in Journal of Gynecologic Oncology (January 2024)